Cover Image
市場調查報告書

難治性多發性骨髓瘤:全球臨床實驗檢討

Refractory Multiple Myeloma Global Clinical Trials Review, H2, 2014

出版商 GlobalData 商品編碼 299737
出版日期 內容資訊 英文 135 Pages
訂單完成後即時交付
價格
Back to Top
難治性多發性骨髓瘤:全球臨床實驗檢討 Refractory Multiple Myeloma Global Clinical Trials Review, H2, 2014
出版日期: 2014年10月31日 內容資訊: 英文 135 Pages
簡介

本報告提供難治性的多發性骨髓瘤相關的臨床研究最新趨勢分析,提供疾病·治療方法概要,及主要已開發國家·新興國家的臨床實驗狀況,各地區、各階段、Phase別的進行狀況,彙整有潛力的贊助商,各企業及研究機關的研究進行狀況,有潛力的藥劑比較等資訊,為您概述為以下內容。

目錄

簡介

  • 難治性多發性骨髓瘤
  • 本報告概要

各地區的臨床實驗情形

  • 各國臨床實驗數量和平均實驗人數
    • 亞太地區前五名國家的臨床實驗數量
    • 歐洲前五名國家的臨床實驗數量
    • 北美的主要國家的臨床實驗數量
    • 中東·非洲的主要國家的臨床實驗數量
    • 中南美前五名國家的臨床實驗數量

在G7各國臨床實驗數量:佔腫瘤整體比率

在G7各國臨床實驗數量:各階段(Phase別)

在G7各國臨床實驗數量:各進展狀況

在E7各國臨床實驗數量:佔腫瘤整體比率

在E7各國臨床實驗數量:各階段(Phase別)

在E7各國臨床實驗數量:各進展狀況

各階段(Phase別)臨床實驗數量

  • 進行中的臨床實驗:Phase別

各進展狀況臨床實驗數量

臨床實驗的目標的成就情形

未完成的臨床實驗數量

一定期間所採用的實驗對象

贊助商的不同種類的臨床實驗數量

有潛力的贊助商

  • 參加難治性多發性骨髓瘤的治療藥臨床實驗的前幾名企業

有潛力的藥劑

臨床實驗的最新趨勢(全5件)

臨床實驗簡介

  • 代表性企業臨床實驗概要
    • Celgene Corporation
    • Amgen Inc.
    • Johnson & Johnson
    • Takeda Pharmaceutical Company Limited
    • Novartis AG
    • Merck & Co., Inc.
    • F. Hoffmann-La Roche Ltd.
    • Pfizer Inc.
    • Bristol-Myers Squibb Company
    • AbbVie Inc.
  • 有代表性的研究機關·醫院臨床實驗概要
    • National Cancer Institute
    • Fred Hutchinson Cancer Research Center
    • Mayo Clinic
    • The University of Texas M. D. Anderson Cancer Center
    • University of Arkansas
    • Case Comprehensive Cancer Center
    • Memorial Sloan Kettering Cancer Center
    • City of Hope National Medical Center
    • Washington University School of Medicine

5個有代表性的臨床實驗簡介

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC2388CTIDB

GlobalData's clinical trial report, "Refractory Multiple Myeloma Global Clinical Trials Review, H2, 2014" provides data on the Refractory Multiple Myeloma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Refractory Multiple Myeloma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Refractory Multiple Myeloma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each
  • Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
  • Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons to buy

  • Understand the dynamics of a particular indication in a condensed manner
  • Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more
  • Obtain discontinued trial listing for trials across the globe
  • Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Refractory Multiple Myeloma
    • Report Guidance
  • Clinical Trials by Region
    • Clinical Trials and Average Enrollment by Country
      • Top Five Countries Contributing to Clinical Trials in Asia-Pacific
      • Top Five Countries Contributing to Clinical Trials in Europe
      • Top Countries Contributing to Clinical Trials in North America
      • Top Countries Contributing to Clinical Trials in Middle East and Africa
      • Top Five Countries Contributing to Clinical Trials in Central and South America
  • Clinical Trials by G7 Countries: Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials
  • Clinical Trials by Phase in G7 Countries
  • Clinical Trials in G7 Countries by Trial Status
  • Clinical Trials by E7 Countries: Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials
  • Clinical Trials by Phase in E7 Countries
  • Clinical Trials in E7 Countries by Trial Status
  • Clinical Trials by Phase
    • In Progress Trials by Phase
  • Clinical Trials by Trial Status
  • Clinical Trials by End Point Status
  • Unaccomplished Trials of Refractory Multiple Myeloma
  • Subjects Recruited Over a Period of Time
  • Clinical Trials by Sponsor Type
  • Prominent Sponsors
    • Top Companies Participating in Refractory Multiple Myeloma Therapeutics Clinical Trials
  • Prominent Drugs
  • Latest Clinical Trials News on Refractory Multiple Myeloma
    • Aug 29, 2014: Senesco Closes Enrollment in Its Phase 1b/2a SNS01-T Study
    • Aug 13, 2014: Amgen Announces Top-Line Results From Phase 3 Focus Trial of Kyprolis in Patients with Relapsed and Advanced Refractory Multiple Myeloma
  • Clinical Trial Profiles
    • Clinical Trial Overview of Top Companies
      • Celgene Corporation
      • Clinical Trial Overview of Celgene Corporation
      • Takeda Pharmaceutical Company Limited
      • Clinical Trial Overview of Takeda Pharmaceutical Company Limited
      • Novartis AG
      • Clinical Trial Overview of Novartis AG
      • Amgen Inc.
      • Clinical Trial Overview of Amgen Inc.
      • Johnson & Johnson
      • Clinical Trial Overview of Johnson & Johnson
      • Merck & Co., Inc.
      • Clinical Trial Overview of Merck & Co., Inc.
      • Pfizer Inc.
      • Clinical Trial Overview of Pfizer Inc.
      • F. Hoffmann-La Roche Ltd.
      • Clinical Trial Overview of F. Hoffmann-La Roche Ltd.
      • Oncotherapeutics
      • Clinical Trial Overview of Oncotherapeutics
      • Bristol-Myers Squibb Company
      • Clinical Trial Overview of Bristol-Myers Squibb Company
    • Clinical Trial Overview of Top Institutes / Government
      • National Cancer Institute
      • Clinical Trial Overview of National Cancer Institute
      • Fred Hutchinson Cancer Research Center
      • Clinical Trial Overview of Fred Hutchinson Cancer Research Center
      • Mayo Clinic
      • Clinical Trial Overview of Mayo Clinic
      • University of Arkansas
      • Clinical Trial Overview of University of Arkansas
      • University of Texas M. D. Anderson Cancer Center
      • Clinical Trial Overview of University of Texas M. D. Anderson Cancer Center
      • Memorial Sloan Kettering Cancer Center
      • Clinical Trial Overview of Memorial Sloan Kettering Cancer Center
      • City of Hope National Medical Center
      • Clinical Trial Overview of City of Hope National Medical Center
      • Fondazione Neoplasie Sangue Onlus
      • Clinical Trial Overview of Fondazione Neoplasie Sangue Onlus
      • Washington University School of Medicine
      • Clinical Trial Overview of Washington University School of Medicine
  • Five Key Clinical Profiles
  • Appendix
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
    • Source

List of Tables

  • Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Region, 2014*
  • Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials, Europe, Top Five Countries, 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials, North America, Top Countries, 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2014*
  • Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials, G7 Countries (%), 2014*
  • Refractory Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Refractory Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials, E7 Countries (%), 2014*
  • Refractory Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Refractory Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Phase, 2014*
  • Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Phase 2014*
  • Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Refractory Multiple Myeloma Therapeutics, Global, Suspended Clinical Trials, 2014*
  • Refractory Multiple Myeloma Therapeutics, Global, Withdrawn Clinical Trials, 2014*
  • Refractory Multiple Myeloma Therapeutics, Global, Terminated Clinical Trials, 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Refractory Multiple Myeloma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Celgene Corporation, 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Takeda Pharmaceutical Company Limited, 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Amgen Inc., 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson & Johnson, 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Oncotherapeutics, 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Bristol-Myers Squibb Company, 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Fred Hutchinson Cancer Research Center, 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Mayo Clinic, 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Arkansas, 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Texas M. D. Anderson Cancer Center, 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by City of Hope National Medical Center, 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Fondazione Neoplasie Sangue Onlus, 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials Market, Global, Clinical Trials by Washington University School of Medicine, 2014*

List of Figures

  • Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Region (%), 2014*
  • Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2014*
  • Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials, North America, Top Countries (%), 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2014*
  • Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials, G7 Countries (%), 2014*
  • Refractory Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Phase, 2014*
  • Refractory Multiple Myeloma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2014*
  • Proportion of Refractory Multiple Myeloma to Oncology Clinical Trials, E7 Countries (%), 2014*
  • Refractory Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Phase, 2014*
  • Refractory Multiple Myeloma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2014*
  • Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Phase (%), 2014*
  • Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials In Progress by Phase, 2014*
  • Refractory Multiple Myeloma Therapeutics, Global, Clinical Trials by Trial Status, 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, by End Point Status, 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2009-2013
  • Refractory Multiple Myeloma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Key Sponsors, 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2014*
  • Refractory Multiple Myeloma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2014*
  • GlobalData Methodology
Back to Top